Arda Ural

Arda Ural assumed the role of Chief Operating Officer at Health Management Associates (HMA) on July 6, 2026, the national leader in health and human services consulting. Ural is an accomplished and innovative healthcare executive with over 30 years of leadership experience, and his operational expertise has led to profitable growth across the professional services and life sciences industries. Based in HMA's New York City office, Ural brings strategic vision to HMA's mission of addressing healthcare and human services challenges.

Ural holds an MBA and a PhD in finance and strategy from Marmara University, Turkey, and a BSc and MSc in mechanical engineering and material science from Bogazici University, Turkey. In 2024 he was recognized as a PharmaVoice 100 Standout Leader thanks to his impact on the industry. He is a frequent speaker at industry conferences and is the Chair of BioNJ C-Suite Summit, demonstrating his standing as a thought leader.

Career history

• Americas Life Sciences Leader at Ernst & Young (EY) – For the last four years, he has been leading the Life Sciences sector, which is a complex business comprising of strategy, consulting, M&A, technology, tax, and assurance capabilities to surpass $2.0B in revenue with consistent profitable growth
• Managing Director at Accenture, where he led the firm's Life Sciences M&A Practice
• VP of Strategic Marketing and a BU Lead at Becton Dickinson, a Fortune 500 medical technology company
• Senior Vice President of Marketing & Sales at Eyetech Pharmaceuticals, a biotech startup that went public and was acquired by OSI/Astellas
• Leadership roles at Pfizer Inc., where he led major brand management for Celebrex and Viagra

What Arda Ural could bring to Chief Operating Officer at Health Management Associates: Ural's appointment as COO represents a significant strategic move that reflects HMA's ambition to scale operations and deepen its healthcare consulting services. His extensive experience in operational transformation, strategic business development, and M&A activities, demonstrated through his leadership of EY's multi-billion-dollar Life Sciences business, positions him to drive HMA's expansion and profitability. His track record in executing organizational change within professional services and his recognized expertise in healthcare policy and industry dynamics suggest he is uniquely equipped to strengthen HMA's operational infrastructure, enhance client value propositions, and capitalize on growth opportunities in the evolving healthcare consulting landscape.

This is an automatically generated Light profile created by Executive Moves editorial systems from verified public announcements. Information is kept deliberately concise until the page is claimed and enriched.